• Neonatal Medicine
• /
• v.15 no.2
• /
• pp.113-118
• /
• 2008

Clinical trials in neonates of different gestational age, birth weight, postnatal age and general health status are needed to assure safe and optimal evidence-based-therapy to this special population. Pharmacodynamic maturation must be considered in grouping the neonates for clinical trials. Informed consent from the parents, protection of the neonates participating in the clinical trials, adherence to good clinical practice guidelines, and designation of short term and long term outcomes must be taken into consideration from the beginning of the trials. Collaboration between centers will be helpful in overcoming the problem with small patient size. Many of these challenges are surmountable and an well-designed clinical trial will improve the mortality and morbidity in these very small children.

• Korean Journal of Pharmacognosy
• /
• v.29 no.3
• /
• pp.248-253
• /
• 1998

Antiallergic activity of the aqueous extract of Menthae herba (MHAE) was investigated in mice and rats. MHAE inhibited systemic anaphylaxis induced by compound 48/80 in mice. Especially, MHAE inhibited compound 48/80 induced systemic anaphylaxis 100% with a dose of 500 mg/kg body weight. MHAE significantly inhibited serum histamine levels induced by compound 48/80. MHAE inhibited histamine release from the rat peritoneal mast cells activated by compound 48/80 or anti-DNP IgE. Our studies provide evidence that MHAE will be beneficial in the treatment of anaphylaxis.

• Journal of Information Processing Systems
• /
• v.15 no.6
• /
• pp.1489-1502
• /
• 2019

This work introduces a novel unweighted combination method (UCSS) for business failure perdition (BFP). With considering features of BFP in the age of big data, UCSS integrates the quantitative and qualitative analysis by utilizing soft set theory (SS). We adopt the conventional expert system (ES) as the basic qualitative classifier, the logistic regression model (LR) and the support vector machine (SVM) as basic quantitative classifiers. Unlike other traditional combination methods, we employ soft set theory to integrate the results of each basic classifier without weighting. In this way, UCSS inherits the advantages of ES, LR, SVM, and SS. To verify the performance of UCSS, it is applied to real datasets. We adopt ES, LR, SVM, combination models utilizing the equal weight approach (CMEW), neural network algorithm (CMNN), rough set and D-S evidence theory (CMRD), and the receiver operating characteristic curve (ROC) and SS (CFBSS) as benchmarks. The superior performance of UCSS has been verified by the empirical experiments.

• YAKHAK HOEJI
• /
• v.42 no.4
• /
• pp.403-407
• /
• 1998

Effects of the aqueous extract of Cimicifuga heracleifolia (CHAE) on the allergic reactions were investigated. CHAE inhibited systemic anaphylaxis induced by compound 48/ 80 in mice dose-dependently. Especially, CHAE inhibited compound 48/80-induced systemic anaphylaxis 100% with a dose of 0.5mg/g body weight. CHAE significantly inhibited serum histamine levels induced by compound 48/80. CHAE inhibited histamine release from the rat peritonea] mast cells activated by compound 48/80 or anti-DNP IgE. Our studies provide evidence that CHAE will be beneficial in the treatment of anaphylias.

• Microbiology and Biotechnology Letters
• /
• v.16 no.6
• /
• pp.438-442
• /
• 1988

The enzyme produced by Rhizopus japonicus was able to convert selectively ginsenoside-Rb$_1$which is the most abundant ginseng saponin, into ginsenoside-Rd which was known to be superior to ginsenoside-Rb$_1$pharmaceutically. The convertible enzyme was purified homogeneous from wheat bran culture of Rhizopus japonicus by ammonium sulfate fractionation and column chromatography of TEAE-cellulose, DEAE-Sephadex A-50, Sephadex G-150, Sepharose 2B. Specific activity of the purified enzyme was increased to a bent 96 folds and yield was appeared to be 11% of culture extract. Evidence for homogenity was obtained from polyacrylamide and SDS-polyacrylamide gel electrophoresis. Molecular weight of the enzyme was estimated about 88, 000 daltons by Sephadex G-l50 gel filtration and SDS-polyacrylamide gel electrophoresis, and it did not consist of any subunit.

• Neonatal Medicine
• /
• v.16 no.2
• /
• pp.131-136
• /
• 2009

Preterm infants are frequently discharged from the hospital with growth retardation. Given the potentially lifelong effects of growth impairmnet during a critical time of development, considerable effort should be focused on improving growth after discharge. Growth monitoring must be based on regular measurements of weight, length, and head circumference to identify those preterm infants with poor growth that may need additional nutritional support. Although prior studies vary in design and the intervention used, the evidence supports the use of fortified formulas in formula-fed preterm infants after discharge. The situation for infants fed human milk is much less clear, it seems prudent to concentrate our efforts on the encouragement of breast-feeding in this population. Catch up growth may have many benefits, and may lead to improved development. However, its long-term metabolic consequences are currently unclear. Understanding the optimal means of providing nutrition after discharge is an ongoing process.

• Biomolecules & Therapeutics
• /
• v.4 no.3
• /
• pp.232-238
• /
• 1996

The physical dependence potency of DA-5018, a non-narcotic analgesic agent, was tested in mice dosed with 0.5 and 4 mg/kg/day for 2 months and daily increasing doses of 1, 2, 4, 6, 8 and 10 mg/kg over 10 days. Physical dependence was assessed taking natural withdrawal induced morphine-type abstinence (jumping, falling, biting or backward locomotion, rearing etc.) as well as barbiturates-type abstinence (body weight reduction, convulsion, ataxia etc.) into consideration. The results were compared with those after the same daily increasing doses of morphine. DA-5018 did not show evidence of physical dependence liability or abuse potential as measured by morphine-type or barbiturate-type abstinence signs following daily increasing or 2-month repeated administration. On the other hand, daily increasing doses of morphine produced physical dependence and the dependent state disappeared about 6 hours after the start of withdrawal signs. In the single dose suppression test, a single dose of morphine completely suppressed natural withdrawal signs that appeared in morphine-dependent animals. Therefore, these results indicate that DA-5018 does not have abuse potential and physical dependence liability.

• Toxicological Research
• /
• v.22 no.2
• /
• pp.135-144
• /
• 2006

This study was performed to evaluate repeated-dose toxicities of STB-HO-BM in Sprague-Dawley rats. STB-HO-BM was administered orally to rats at dose levels of 0, 100, 300 and 1,000 mg/kg/day for 13 weeks. In recent study, there were no dose related changes in mortality, clinical signs, body weight changes, food and water consumption, opthalmoscopy, organ weights, urine analysis, hematological findings, and biochemical examination of all animals treated with STB-HO-BM. Gross and histopathological findings revealed no evidence of specific toxicity related to STB-HO-BM. These results suggest that the oral no observed adverse effect level (NOAEL) of STB-HO-BM may be over 1,000 mg/kg in rats.

• Toxicological Research
• /
• v.17 no.2
• /
• pp.107-114
• /
• 2001

This study was designed to evaluate a repeated oral dose toxicity of a new hepatotherapeutic agent GODEX in Sprague-Dawley rats. Male and female rats were orally administered with dosages of 500, 100, 20, and 0 /kg/day of GODEX daily for 4 weeks, respectively. There were no dose-related changes in clinical signs, body weight changes, food and water consumption, opthalmoscopy, organ weights, urine analysis, biochemical examination, and hematological findings of all animals treated with GODEX. Gross and histopathological findings revealed no evidence of specific toxicity related to GODEX. These indicate that GODEX may have no side effects and its oral maximum tolerated dose value may be over 500 mg/kg in rats.

• Biomolecules & Therapeutics
• /
• v.4 no.2
• /
• pp.202-204
• /
• 1996

Clonidine, an antihypertensive drug, stimulates postsynaptic $\alpha_2$adrenergic receptors in the CNS and lowers arterial pressure by erects on both cardiac output and peripheral resistance. However, many patients experience that sedation and xerostomia occured upon oral administration of clonidine. These side effects are due to high plasma peak concentration and can be avoided when clonidine is given transdermally. In this study, we performed the skin irritation test for transdermal administration of clonidine patch on New Zealand white rabbits. Twelve New Zealand white rabbits were divided into two groups according to the dose levels, respectively. After transdermal administration of clonidine patch with two doses, clinical manifestations, body weight loss and postmortem findings were observed. We could not find any significant evidence of skin irritation by transdermal administration of clonidine patch.